{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:31:50Z","timestamp":1792758710012,"version":"4.5.0"},"reference-count":308,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,2]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Acute leukemia is a hematologic malignancy that affects people of all ages. Immunotherapies, including T-cell engagers, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies have contributed to a paradigm shift in the treatment of patients with acute leukemia. Combined with advancements in allogeneic hematopoietic stem cell transplant and targeted therapy development, patients with acute leukemia have additional effective treatment options, providing the possibility of long-term remission. However, these advances have resulted in a complex and dynamic treatment landscape for clinicians to navigate. To guide the oncology community and provide a framework for patient care, the Society for Immunotherapy of Cancer convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of acute leukemia. Drawing from published data and clinical experience, the Expert Panel developed evidence-based and consensus-based recommendations relating to diagnostics; immunotherapies for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, and blastic plasmacytoid dendritic cell neoplasm; toxicity and safety management; treatment sequencing; and patient education and quality of life.<\/jats:p>","DOI":"10.1136\/jitc-2026-015963","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:11:28Z","timestamp":1789999888000},"page":"e015963","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct01466179","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01471782","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02013167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02013167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02000427","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02101853","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187354","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01207388","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02003222","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03914625","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02393859","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01564784","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02981628","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03739814","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03460522","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00558519","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02393859","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02877303","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02435849","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02614066","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04404660","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00927498","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00372593","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02724163","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00091234","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02113982","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00893399","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N","family":"Shah","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, University of Warwick, Coventry, UK"},{"name":"Centre for Clinical Haematology, University Hospitals, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado and Children\u2019s Hospital Colorado, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-8246","authenticated-orcid":false,"given":"Monica L","family":"Guzman","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra R","family":"Lovell","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Luciani","sequence":"additional","affiliation":[{"name":"University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5814-0984","authenticated-orcid":false,"given":"Ravindra","family":"Majeti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-8736","authenticated-orcid":false,"given":"Shannon L","family":"Maude","sequence":"additional","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology, Intermountain Primary Children\u2019s Hospital\/Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Sallman","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal D","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"The University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"Med. Klinik und Poliklinik III, LMU - Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-1662","authenticated-orcid":false,"given":"Sarah K","family":"Tasian","sequence":"additional","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA"},{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L","family":"Wood","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Children\u2019s Hospital of Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Yates","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092107100876000_14.9.e015963.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2026092107100876000_14.9.e015963.2","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026092107100876000_14.9.e015963.3","doi-asserted-by":"crossref","unstructured":"Venugopal S , Sekeres MA . Contemporary management of acute myeloid leukemia: a review. JAMA Oncol 2024.","DOI":"10.1001\/jamaoncol.2024.2662"},{"key":"2026092107100876000_14.9.e015963.4","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"The Lancet"},{"key":"2026092107100876000_14.9.e015963.5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026092107100876000_14.9.e015963.6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jtct.2022.06.005","article-title":"Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy","volume":"28","author":"Tarlock","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026092107100876000_14.9.e015963.7","unstructured":"Food and Drug Administration (FDA), Novartis Pharmaceuticals Corporation . Tisagenlecleucel (KYMRIAH) prescribing information."},{"key":"2026092107100876000_14.9.e015963.8","unstructured":"Food and Drug Administration (FDA), Kite Pharmaceuticals . Brexucabtagene autoleucel (TECARTUS) prescribing information. n.d. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus"},{"key":"2026092107100876000_14.9.e015963.9","unstructured":"Food and Drug Administration (FDA), Autolus Limited . Obecabtagene autoleucel (AUCATZYL) prescribing information. n.d. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl"},{"key":"2026092107100876000_14.9.e015963.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000810","article-title":"The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia","volume":"8","author":"Boyiadzis","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026092107100876000_14.9.e015963.11","unstructured":"RAND . RAND\/UCLA appropriateness method. RAND; 2001. Available: https:\/\/www.rand.org\/health\/surveys\/appropriateness.html"},{"key":"2026092107100876000_14.9.e015963.12","unstructured":"The oxford levels of evidence 2. OCEBM Levels of Evidence Working Group. n.d. Available: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence"},{"key":"2026092107100876000_14.9.e015963.13","unstructured":"Shah B , Mattison RJ , Abboud R , et al . Acute lymphoblastic leukemia, version 2.2025, nccn clinical practice guidelines in oncology 2025 [563-76]. 2025. Available: www.nccn.org"},{"key":"2026092107100876000_14.9.e015963.14","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.5858\/arpa.2016-0504-CP","article-title":"Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology","volume":"141","author":"Arber","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2026092107100876000_14.9.e015963.15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.18.01468","article-title":"Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline","volume":"37","author":"de Haas","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.16","unstructured":"Zwaan CM , Tasian SK , Aplenc R , et al . Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel. Blood Journal 2025;2024027904."},{"key":"2026092107100876000_14.9.e015963.17","unstructured":"Pollyea DA , Altman JK , Assi R , et al . Acute myeloid leukemia, version 3.2026, nccn clinical practice guidelines in oncology. 2025. Available: www.ncccn.org"},{"key":"2026092107100876000_14.9.e015963.18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cancergen.2020.03.001","article-title":"Evidence-based review of genomic aberrations in B-lymphoblastic leukemia\/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia","volume":"243","author":"Akkari","year":"2020","journal-title":"Cancer Genet"},{"key":"2026092107100876000_14.9.e015963.19","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0300060518819637","article-title":"Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia","volume":"47","author":"Ouyang","year":"2019","journal-title":"J Int Med Res"},{"key":"2026092107100876000_14.9.e015963.20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.312"},{"key":"2026092107100876000_14.9.e015963.21","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.2022017035","article-title":"How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia","volume":"141","author":"Kopmar","year":"2023","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.23","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1080\/10428194.2024.2392823","article-title":"The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia","volume":"65","author":"Ngo","year":"2024","journal-title":"Leukemia & Lymphoma"},{"key":"2026092107100876000_14.9.e015963.24","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3324\/haematol.2023.283275","article-title":"Central nervous system therapy in acute lymphoblastic leukemia: no more, no less","volume":"108","author":"Rives","year":"2023","journal-title":"Haematologica"},{"key":"2026092107100876000_14.9.e015963.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01714-x"},{"key":"2026092107100876000_14.9.e015963.26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s11864-022-01032-5","article-title":"Central Nervous System Prophylaxis and Treatment in Acute Leukemias","volume":"23","author":"Wu","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2026092107100876000_14.9.e015963.27","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2024015779","article-title":"Outcomes of brexucabtagene autoleucel in patients with relapsed\/refractory acute lymphoblastic leukemia with CNS involvement","volume":"9","author":"Muhsen","year":"2025","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.28","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1182\/bloodadvances.2025018604","article-title":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multisite, retrospective cohort review","volume":"10","author":"Rankin","year":"2026","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.29","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.30","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"key":"2026092107100876000_14.9.e015963.31","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026092107100876000_14.9.e015963.32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.blre.2018.03.006","article-title":"Time to repeal and replace response criteria for acute myeloid leukemia?","volume":"32","author":"Bloomfield","year":"2018","journal-title":"Blood Rev"},{"key":"2026092107100876000_14.9.e015963.33","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0095"},{"key":"2026092107100876000_14.9.e015963.34","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","article-title":"Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia","volume":"6","author":"Grover","year":"2022","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003"},{"key":"2026092107100876000_14.9.e015963.36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081847","article-title":"Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions","volume":"13","author":"Contreras Yametti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026092107100876000_14.9.e015963.37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/ijlh.13923","article-title":"To B- or not to B-: A review of lineage switched acute leukemia","volume":"44 Suppl 1","author":"Kurzer","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"2026092107100876000_14.9.e015963.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-00983-2","article-title":"Genetics and pathologic landscape of lineage switch of acute leukemia during therapy","volume":"14","author":"Zhou","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026092107100876000_14.9.e015963.40","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29939","article-title":"Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia","volume":"70","author":"McCall","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"2026092107100876000_14.9.e015963.41","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"2026092107100876000_14.9.e015963.43","unstructured":"Food and Drug Administration (FDA) . Blinatumomab (BLINCYTO) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125557"},{"key":"2026092107100876000_14.9.e015963.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"2026092107100876000_14.9.e015963.45","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.46","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41375-020-0770-8","article-title":"Blinatumomab versus historical standard therapy in pediatric patients with relapsed\/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Locatelli","year":"2020","journal-title":"Leukemia"},{"key":"2026092107100876000_14.9.e015963.47","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0179"},{"key":"2026092107100876000_14.9.e015963.48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783"},{"key":"2026092107100876000_14.9.e015963.49","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leukemia & Lymphoma"},{"key":"2026092107100876000_14.9.e015963.50","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome\u2013Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0987"},{"key":"2026092107100876000_14.9.e015963.52","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29715","article-title":"Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia","volume":"69","author":"Locatelli","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2026092107100876000_14.9.e015963.53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0669"},{"key":"2026092107100876000_14.9.e015963.54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02200"},{"key":"2026092107100876000_14.9.e015963.55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005579"},{"key":"2026092107100876000_14.9.e015963.56","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014043"},{"key":"2026092107100876000_14.9.e015963.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"2026092107100876000_14.9.e015963.58","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2026092107100876000_14.9.e015963.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"2026092107100876000_14.9.e015963.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680"},{"key":"2026092107100876000_14.9.e015963.61","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214171"},{"key":"2026092107100876000_14.9.e015963.63","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092107100876000_14.9.e015963.64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01075"},{"key":"2026092107100876000_14.9.e015963.65","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.66","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.67","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026092107100876000_14.9.e015963.68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2019.02.009","article-title":"Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"79","author":"King","year":"2019","journal-title":"Leuk Res"},{"key":"2026092107100876000_14.9.e015963.69","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131838","article-title":"Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias","volume":"134","author":"McCloskey","year":"2019","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.70","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117400","article-title":"Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience","volume":"132","author":"Alfayez","year":"2018","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.71","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09848-z"},{"key":"2026092107100876000_14.9.e015963.72","doi-asserted-by":"crossref","first-page":"804714","DOI":"10.3389\/fonc.2021.804714","article-title":"Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed\/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"11","author":"Bonifacio","year":"2022","journal-title":"Front Oncol"},{"key":"2026092107100876000_14.9.e015963.73","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.74","doi-asserted-by":"crossref","first-page":"921894","DOI":"10.3389\/fimmu.2022.921894","article-title":"Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"2026092107100876000_14.9.e015963.75","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(25)01554-X","article-title":"ALL-774: Safety and Efficacy of AZD0486 in Adolescent and Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Early Results From the Phase 1\/2 SYRUS Study","volume":"25","author":"Aldoss","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2026092107100876000_14.9.e015963.76","unstructured":"Food and Drug Administration (FDA), Wyeth Pharms Inc . Inotuzumab ozogamicin (BESPONSA) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761040"},{"key":"2026092107100876000_14.9.e015963.77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"2026092107100876000_14.9.e015963.78","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"2026092107100876000_14.9.e015963.79","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007848"},{"key":"2026092107100876000_14.9.e015963.80","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"2026092107100876000_14.9.e015963.81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01693"},{"key":"2026092107100876000_14.9.e015963.82","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026092107100876000_14.9.e015963.83","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.clml.2023.12.016","article-title":"Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia","volume":"24","author":"Short","year":"2024","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2026092107100876000_14.9.e015963.84","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"American J Hematol"},{"key":"2026092107100876000_14.9.e015963.85","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.86","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-444","article-title":"Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival","volume":"146","author":"Wieduwilt","year":"2025","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.87","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026092107100876000_14.9.e015963.88","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.89","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","article-title":"Inotuzumab ozogamicin in combination with low\u2010intensity chemotherapy (mini\u2010HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome\u2010negative acute lymphoblastic leukemia: A propensity score analysis","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"key":"2026092107100876000_14.9.e015963.90","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.91","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961"},{"key":"2026092107100876000_14.9.e015963.93","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-209438","article-title":"Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.94","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-149478","article-title":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children\u2019s Oncology Group Protocol AALL1732","volume":"138","author":"McNeer","year":"2021","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.10016"},{"key":"2026092107100876000_14.9.e015963.96","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2023022330","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour","year":"2024","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.97","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/S2152-2650(25)01538-1","article-title":"ALL-562: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose","volume":"25","author":"Jabbour","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2026092107100876000_14.9.e015963.98","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00418-1"},{"key":"2026092107100876000_14.9.e015963.99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026092107100876000_14.9.e015963.100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642"},{"key":"2026092107100876000_14.9.e015963.101","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"2026092107100876000_14.9.e015963.102","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","article-title":"FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"key":"2026092107100876000_14.9.e015963.103","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"The Lancet"},{"key":"2026092107100876000_14.9.e015963.104","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026092107100876000_14.9.e015963.105","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02532-7"},{"key":"2026092107100876000_14.9.e015963.106","unstructured":"Oluwole O , Ghobadi A , Cassaday R , et al . Five-year survival outcomes of patients (pts) with relapsed or refractory b-cell acute lymphoblastic leukemia. EHA Library, 2025."},{"key":"2026092107100876000_14.9.e015963.107","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed\/Refractory B-Cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.108","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2024014846","article-title":"Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy","volume":"9","author":"Lust","year":"2025","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.109","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3324\/haematol.2022.280678","article-title":"Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"108","author":"Wayne","year":"2022","journal-title":"Haematol"},{"key":"2026092107100876000_14.9.e015963.110","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1200\/JCO.2024.42.16_suppl.6504","article-title":"Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib\/II study","volume":"42","author":"Jabbour","year":"2024","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526"},{"key":"2026092107100876000_14.9.e015963.112","doi-asserted-by":"crossref","unstructured":"Shah BD , Yallop D , Jabbour E , et al . Efficacy and safety outcomes of obecabtagene autoleucel (Obe-Cel). In: Stratified By Age In Patients With Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia (R\/R B-All). EHA Library, 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.6576"},{"key":"2026092107100876000_14.9.e015963.113","doi-asserted-by":"crossref","unstructured":"Muffly L , Frey NV , Roloff GW , et al . Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study. Blood Journal 2026;2026033559. doi:10.1182\/blood.2026033559","DOI":"10.1182\/blood.2026033559"},{"key":"2026092107100876000_14.9.e015963.114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"2026092107100876000_14.9.e015963.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"2026092107100876000_14.9.e015963.116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01405"},{"key":"2026092107100876000_14.9.e015963.117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001466"},{"key":"2026092107100876000_14.9.e015963.118","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.119","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01272-6"},{"key":"2026092107100876000_14.9.e015963.120","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1182\/bloodadvances.2025016149","article-title":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis","volume":"9","author":"Rangarajan","year":"2025","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.121","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011184"},{"key":"2026092107100876000_14.9.e015963.122","first-page":"514","article-title":"Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel","volume":"21","author":"Leone","year":"2023","journal-title":"Blood Transfus"},{"key":"2026092107100876000_14.9.e015963.123","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.335","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2022","journal-title":"EJHaem"},{"key":"2026092107100876000_14.9.e015963.124","first-page":"72","article-title":"Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children\/Young Adults with Relapsed\/Refractory B Cell Acute Lymphoblastic Leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026092107100876000_14.9.e015963.125","doi-asserted-by":"crossref","unstructured":"Baruchel A . Bridging to car-t cells in children, adolescents, and young adults with all. In: The EBMT\/EHA CAR-T Cell Handbook. 2022: 115\u20138.","DOI":"10.1007\/978-3-030-94353-0_21"},{"key":"2026092107100876000_14.9.e015963.126","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000692"},{"key":"2026092107100876000_14.9.e015963.127","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study","volume":"13","author":"Niu","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026092107100876000_14.9.e015963.128","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"The Lancet"},{"key":"2026092107100876000_14.9.e015963.129","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood.2025028790","article-title":"Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion","volume":"146","author":"Roddie","year":"2025","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"2026092107100876000_14.9.e015963.131","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int"},{"key":"2026092107100876000_14.9.e015963.132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-794214"},{"key":"2026092107100876000_14.9.e015963.133","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.134","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007059"},{"key":"2026092107100876000_14.9.e015963.135","first-page":"4676375","article-title":"Anti-CD7 allogeneic WU-CART-007 in patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma: a phase 1\/2 trial","volume":"3","author":"Ghobadi","year":"2024","journal-title":"Res Sq"},{"key":"2026092107100876000_14.9.e015963.136","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.beha.2023.101485","article-title":"The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia","volume":"36","author":"Prockop","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026092107100876000_14.9.e015963.137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.014"},{"key":"2026092107100876000_14.9.e015963.138","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"key":"2026092107100876000_14.9.e015963.139","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT\u2010PCR for BCR:: ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"key":"2026092107100876000_14.9.e015963.140","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.2023023754","article-title":"NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients","volume":"144","author":"Simonin","year":"2024","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.141","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2017.04.003","article-title":"Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia","volume":"23","author":"Hamilton","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026092107100876000_14.9.e015963.142","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1200\/JCO.2025.43.16_suppl.6559","article-title":"Allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia adults in complete remission: A systematic review and meta-analysis","volume":"43","author":"Mushtaq","year":"2025","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.143","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3109\/10428194.2016.1160080","article-title":"Evaluation of allogeneic transplantation in first or later minimal residual disease \u2013 negative remission following adult-inspired therapy for acute lymphoblastic leukemia","volume":"57","author":"Cassaday","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2026092107100876000_14.9.e015963.144","doi-asserted-by":"crossref","first-page":"651944","DOI":"10.3389\/fonc.2021.651944","article-title":"Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"2026092107100876000_14.9.e015963.145","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016937"},{"key":"2026092107100876000_14.9.e015963.146","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/curroncol32030177","article-title":"The Changing Role of Allogeneic Stem Cell Transplantation in Adult B-ALL in the Era of CAR T Cell Therapy","volume":"32","author":"van den Berg","year":"2025","journal-title":"Current Oncology"},{"key":"2026092107100876000_14.9.e015963.147","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MOH.0000000000000685","article-title":"Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia","volume":"28","author":"Qayed","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"2026092107100876000_14.9.e015963.148","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01101-z"},{"key":"2026092107100876000_14.9.e015963.149","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"},{"key":"2026092107100876000_14.9.e015963.150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtct.2021.03.026","article-title":"Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplantation and Cellular Therapy"},{"key":"2026092107100876000_14.9.e015963.151","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2022.101082","article-title":"Optimizing Management of the Central Nervous System in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplantation","volume":"8","author":"Patel","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"2026092107100876000_14.9.e015963.152","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-03913-6","article-title":"Adverse events in the nervous system associated with blinatumomab: a real-world study","volume":"23","author":"Gao","year":"2025","journal-title":"BMC Med"},{"key":"2026092107100876000_14.9.e015963.153","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bbmt.2015.10.016","article-title":"Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia","volume":"22","author":"Aldoss","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026092107100876000_14.9.e015963.154","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.prro.2018.12.005","article-title":"The Impact of Low-Dose Cranial Boost on the Long-Term Outcomes of Adult Patients with High-Risk Acute Lymphoblastic Leukemia Undergoing Total Body Irradiation and Allogeneic Hematopoietic Stem Cell Transplantation","volume":"9","author":"Famoso","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"2026092107100876000_14.9.e015963.155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10428194.2020.1827247","article-title":"Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin","volume":"62","author":"Ladha","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026092107100876000_14.9.e015963.156","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.2021012412","article-title":"How I treat with maintenance therapy after allogeneic HCT","volume":"141","author":"DeFilipp","year":"2023","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.157","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.bbmt.2019.09.022","article-title":"Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review","volume":"26","author":"Warraich","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026092107100876000_14.9.e015963.158","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826"},{"key":"2026092107100876000_14.9.e015963.159","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","article-title":"Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study","volume":"107","author":"Greinix","year":"2021","journal-title":"Haematol"},{"key":"2026092107100876000_14.9.e015963.160","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1182\/bloodadvances.2024012722","article-title":"Decreasing chronic graft-versus-host disease rates in all populations","volume":"8","author":"Carpenter","year":"2024","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.161","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026092107100876000_14.9.e015963.162","unstructured":"Loren AW , Mielcarke M , Angelos M , et al . Hematopoietic cell transplantation version 3.2025, nccn clinical practice guidelines in oncology. 2025. Available: www.nccn.org"},{"key":"2026092107100876000_14.9.e015963.163","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.005"},{"key":"2026092107100876000_14.9.e015963.164","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1182\/bloodadvances.2025017011","article-title":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML","volume":"9","author":"Naik","year":"2025","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041944","article-title":"Emerging Immunotherapy for Acute Myeloid Leukemia","volume":"22","author":"Tabata","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026092107100876000_14.9.e015963.166","doi-asserted-by":"crossref","first-page":"102546","DOI":"10.1016\/j.coph.2025.102546","article-title":"Precision medicine and immunotherapeutic approaches for relapsed\/refractory paediatric acute myeloid leukaemia","volume":"83","author":"Smith","year":"2025","journal-title":"Curr Opin Pharmacol"},{"key":"2026092107100876000_14.9.e015963.167","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3324\/haematol.2023.283817","article-title":"Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?","volume":"109","author":"Naik","year":"2024","journal-title":"Haematologica"},{"key":"2026092107100876000_14.9.e015963.168","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2026092107100876000_14.9.e015963.169","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"2026092107100876000_14.9.e015963.170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0255"},{"key":"2026092107100876000_14.9.e015963.171","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5"},{"key":"2026092107100876000_14.9.e015963.172","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26190"},{"key":"2026092107100876000_14.9.e015963.173","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-762336"},{"key":"2026092107100876000_14.9.e015963.174","unstructured":"Food and Drug Administration (FDA), Wyeth Pharms Inc . Gemtuzumab ozogamicin (MYLOTARG) prescribing information."},{"key":"2026092107100876000_14.9.e015963.175","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"2026092107100876000_14.9.e015963.176","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"2026092107100876000_14.9.e015963.177","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"key":"2026092107100876000_14.9.e015963.178","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.3628"},{"key":"2026092107100876000_14.9.e015963.180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254441"},{"key":"2026092107100876000_14.9.e015963.181","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ajh.23795","article-title":"Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG\u2010GO) as front\u2010line regimen in patients with core binding factor acute myelogenous leukemia","volume":"89","author":"Borthakur","year":"2014","journal-title":"American J Hematol"},{"key":"2026092107100876000_14.9.e015963.182","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"2026092107100876000_14.9.e015963.183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"2026092107100876000_14.9.e015963.184","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00943"},{"key":"2026092107100876000_14.9.e015963.185","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198419","article-title":"Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial","volume":"144","author":"Gibson","year":"2024","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.186","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"2026092107100876000_14.9.e015963.187","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03048"},{"key":"2026092107100876000_14.9.e015963.188","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/bjh.17943","article-title":"Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials","volume":"196","author":"Dillon","year":"2022","journal-title":"Br J Haematol"},{"key":"2026092107100876000_14.9.e015963.189","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041974"},{"key":"2026092107100876000_14.9.e015963.190","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26989"},{"key":"2026092107100876000_14.9.e015963.191","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09\u201309): a randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"D\u00f6hner","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.192","doi-asserted-by":"crossref","unstructured":"Jalte M , Abbassi M , El Mouhi H , et al . FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted Therapies. Cureus 2023;15. doi:10.7759\/cureus.45765","DOI":"10.7759\/cureus.45765"},{"key":"2026092107100876000_14.9.e015963.193","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0357-9"},{"key":"2026092107100876000_14.9.e015963.194","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.26700","article-title":"Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients","volume":"97","author":"Borthakur","year":"2022","journal-title":"Am J Hematol"},{"key":"2026092107100876000_14.9.e015963.195","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","article-title":"A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia","volume":"63","author":"Short","year":"2022","journal-title":"Leukemia & Lymphoma"},{"key":"2026092107100876000_14.9.e015963.196","doi-asserted-by":"publisher","DOI":"10.1182\/blood2022016867"},{"key":"2026092107100876000_14.9.e015963.197","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.03.002"},{"key":"2026092107100876000_14.9.e015963.198","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO-25-00856","article-title":"Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","volume":"43","author":"Al Malki","year":"2025","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.199","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1200\/JCO-25-01884","article-title":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere","volume":"43","author":"Rambaldi","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.200","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ejh.13557","article-title":"Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML","volume":"106","author":"Klyuchnikov","year":"2021","journal-title":"Eur J Haematol"},{"key":"2026092107100876000_14.9.e015963.201","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-829911"},{"key":"2026092107100876000_14.9.e015963.202","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.203","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.204","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4439"},{"key":"2026092107100876000_14.9.e015963.205","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01640-3"},{"key":"2026092107100876000_14.9.e015963.206","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30584","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Myeloid neoplasms","volume":"70","author":"Cooper","year":"2023","journal-title":"Pediatric Blood & Cancer"},{"key":"2026092107100876000_14.9.e015963.207","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00277-022-04965-x","article-title":"Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis","volume":"101","author":"Masetti","year":"2022","journal-title":"Ann Hematol"},{"key":"2026092107100876000_14.9.e015963.208","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1200\/JCO-24-01841","article-title":"Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children\u2019s Oncology Group","volume":"43","author":"Huang","year":"2025","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.209","first-page":"13","article-title":"Chemotherapy versus transplants for acute myelogenous leukemia in second remission","volume":"10","author":"Gale","year":"1996","journal-title":"Leukemia"},{"key":"2026092107100876000_14.9.e015963.210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijrobp.2010.01.062","article-title":"Impact of Cranial Irradiation Added to Intrathecal Conditioning in Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia With Central Nervous System Involvement","volume":"80","author":"Mayadev","year":"2011","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2026092107100876000_14.9.e015963.211","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112015","article-title":"Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia","volume":"16","author":"Parks","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026092107100876000_14.9.e015963.212","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139105"},{"key":"2026092107100876000_14.9.e015963.213","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-177929","article-title":"Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506\/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated","volume":"142","author":"Levis","year":"2023","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.214","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.215","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.216","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.3324\/haematol.2022.281810","article-title":"Maintenance therapy in acute myeloid leukemia: advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"key":"2026092107100876000_14.9.e015963.217","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.895771","article-title":"Maintenance therapy for AML after allogeneic HCT","volume":"12","author":"Nayak","year":"2022","journal-title":"Front Oncol"},{"key":"2026092107100876000_14.9.e015963.218","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01612"},{"key":"2026092107100876000_14.9.e015963.219","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"key":"2026092107100876000_14.9.e015963.220","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2026092107100876000_14.9.e015963.221","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053"},{"key":"2026092107100876000_14.9.e015963.222","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7073","article-title":"A phase 1b\/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax\/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML)","volume":"41","author":"Daver","year":"2023","journal-title":"JCO"},{"key":"2026092107100876000_14.9.e015963.223","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026092107100876000_14.9.e015963.224","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00697"},{"key":"2026092107100876000_14.9.e015963.225","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.3390\/cancers15102713","article-title":"The Black Hole: CAR T Cell Therapy in AML","volume":"15","author":"Atilla","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026092107100876000_14.9.e015963.226","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","article-title":"Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2026092107100876000_14.9.e015963.227","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.281106","article-title":"Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"haematol"},{"key":"2026092107100876000_14.9.e015963.228","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026598"},{"key":"2026092107100876000_14.9.e015963.229","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/PPO.0000000000000635","article-title":"Antibody-Drug Conjugates in Myeloid Leukemias","volume":"28","author":"Senapati","year":"2022","journal-title":"Cancer J"},{"key":"2026092107100876000_14.9.e015963.230","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0202"},{"key":"2026092107100876000_14.9.e015963.231","unstructured":"WHO classification of tumours, haematolymphoid tumours: International agency for research on cancer (IARC). 2022."},{"key":"2026092107100876000_14.9.e015963.232","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2329"},{"key":"2026092107100876000_14.9.e015963.233","unstructured":"Food and Drug Administration (FDA), Stemline Therapeutics . Tagraxofusp-erzs (ELZONRIS) prescribing information."},{"key":"2026092107100876000_14.9.e015963.234","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105"},{"key":"2026092107100876000_14.9.e015963.235","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/01.HS9.0000850164.28901.b2","article-title":"PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED\/FRONTLINE BPDCN","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Hemasphere"},{"key":"2026092107100876000_14.9.e015963.236","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jha2.856","article-title":"Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent\/young adult patients","volume":"5","author":"Pemmaraju","year":"2024","journal-title":"eJHaem"},{"key":"2026092107100876000_14.9.e015963.237","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01968-z"},{"key":"2026092107100876000_14.9.e015963.238","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1002\/pbc.24483","article-title":"Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia","volume":"60","author":"Wright","year":"2013","journal-title":"Pediatric Blood & Cancer"},{"key":"2026092107100876000_14.9.e015963.239","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.026179"},{"key":"2026092107100876000_14.9.e015963.240","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1200\/JCO-25-02083","article-title":"Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"44","author":"Pemmaraju","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092107100876000_14.9.e015963.241","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2026092107100876000_14.9.e015963.242","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v6.0 Cancer Therapy Evaluation Program, National Cancer Institute. 2025. Available: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v6.pdf"},{"key":"2026092107100876000_14.9.e015963.243","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.244","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026092107100876000_14.9.e015963.245","first-page":"438","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026092107100876000_14.9.e015963.246","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.653","article-title":"Incidence of Laboratory Tumor Lysis Syndrome in CAR T-Cell Recipients","volume":"30","author":"Sicre","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"key":"2026092107100876000_14.9.e015963.247","doi-asserted-by":"crossref","unstructured":"Gebremedhen AI , Mohammed A , Souleymane M , et al . Impact of tumor lysis syndrome on clinical outcomes and healthcare burden in chimeric antigen receptor T-cell therapy patients: Key insights from United States population data. JCO 2025;43. doi:10.1200\/JCO.2025.43.16_suppl.e19000","DOI":"10.1200\/JCO.2025.43.16_suppl.e19000"},{"key":"2026092107100876000_14.9.e015963.248","unstructured":"FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor car T cell immunotherapies. 2025."},{"key":"2026092107100876000_14.9.e015963.249","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245746","article-title":"The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review","volume":"15","author":"Hansen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026092107100876000_14.9.e015963.250","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","article-title":"Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention","volume":"8","author":"Furqan","year":"2024","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.251","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013"},{"key":"2026092107100876000_14.9.e015963.252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992"},{"key":"2026092107100876000_14.9.e015963.253","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"2026092107100876000_14.9.e015963.254","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.14100","article-title":"Long\u2010term survivorship care after CAR\u2010T cell therapy","volume":"112","author":"Puckrin","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026092107100876000_14.9.e015963.255","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"2026092107100876000_14.9.e015963.256","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000"},{"key":"2026092107100876000_14.9.e015963.257","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)\u2010T\u2010cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transplant Infectious Dis"},{"key":"2026092107100876000_14.9.e015963.258","unstructured":"Long term follow-up after administration of human gene therapy products. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research; 2020. Available: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Long-Term-Follow-Up-After-Admin-Human-GT-Products_Jan_2020.pdf"},{"key":"2026092107100876000_14.9.e015963.259","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024166"},{"key":"2026092107100876000_14.9.e015963.260","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026092107100876000_14.9.e015963.261","doi-asserted-by":"crossref","unstructured":"Jabbour E , Paul S , Nichols DE , et al . Incidence of central nervous system toxicity and cytokine release syndrome in leukemia patients treated with blinatumomab. Washington, DC American Society of Hematology; 2022.","DOI":"10.1182\/blood-2022-170579"},{"key":"2026092107100876000_14.9.e015963.262","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"2026092107100876000_14.9.e015963.263","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-4-13"},{"key":"2026092107100876000_14.9.e015963.264","doi-asserted-by":"crossref","unstructured":"Li AM , Rabin KR , Kairalla J , et al . Blinatumomab associated seizure risk in patients with down syndrome and b-lymphoblastic leukemia: an interim report from children\u2019s oncology group (cog) study aall1731. Washington, DC American Society of Hematology; 2021.","DOI":"10.1182\/blood-2021-148967"},{"key":"2026092107100876000_14.9.e015963.265","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"2026092107100876000_14.9.e015963.266","unstructured":"Lima MJ , Kebriaei P , Lanza F , et al . Veno-occlusive disease risk and other outcomes in patients with b-cell precursor acute lymphoblastic leukemia who received inotuzumab ozogamicin and proceeded to hematopoietic stem cell transplantation: a registry-based, observational study. Washington, DC American Society of Hematology; 2022."},{"key":"2026092107100876000_14.9.e015963.267","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.024"},{"key":"2026092107100876000_14.9.e015963.268","doi-asserted-by":"crossref","unstructured":"Cheuk DK , Chiang AK , Ha SY , et al . n.d. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2015. doi:10.1002\/14651858.CD009311.pub2","DOI":"10.1002\/14651858.CD009311.pub2"},{"key":"2026092107100876000_14.9.e015963.269","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/10781552241313473","article-title":"Utility of ursodiol prophylaxis against sinusoidal obstruction syndrome (SOS)\/ veno-occlusive disease (VOD) in acute leukemia patients receiving gemtuzumab-ozogamicin (GO) or inotuzumab-ozogamicin (InO)","volume":"32","author":"Mosallam","year":"2026","journal-title":"J Oncol Pharm Pract"},{"key":"2026092107100876000_14.9.e015963.270","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bbmt.2019.12.763","article-title":"Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis","volume":"26","author":"Ho","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"2026092107100876000_14.9.e015963.271","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703602"},{"key":"2026092107100876000_14.9.e015963.272","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","article-title":"Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Ceolin","year":"2023","journal-title":"Leukemia"},{"key":"2026092107100876000_14.9.e015963.273","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-183103","article-title":"Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"142","author":"Rheingold","year":"2023","journal-title":"Blood"},{"key":"2026092107100876000_14.9.e015963.274","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1182\/bloodadvances.2024013747","article-title":"Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL","volume":"8","author":"Aldoss","year":"2024","journal-title":"Blood Adv"},{"key":"2026092107100876000_14.9.e015963.275","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41375-024-02467-5","article-title":"Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study","volume":"39","author":"Ort\u00ed","year":"2025","journal-title":"Leukemia"},{"key":"2026092107100876000_14.9.e015963.276","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jtct.2023.10.024","article-title":"Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia","volume":"30","author":"Llaurador","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026092107100876000_14.9.e015963.277","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12967-025-06399-1","article-title":"Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"23","author":"Cao","year":"2025","journal-title":"J Transl Med"},{"key":"2026092107100876000_14.9.e015963.278","doi-asserted-by":"crossref","first-page":"151445","DOI":"10.1016\/j.soncn.2023.151445","article-title":"Efficacy of a Patient Education Session for Cancer Patients Receiving Immunotherapy","volume":"39","author":"Teixeira-Poit","year":"2023","journal-title":"Semin Oncol Nurs"},{"key":"2026092107100876000_14.9.e015963.279","unstructured":"BMT InfoNet . [What is car t-cell therapy?]. n.d. Available: https:\/\/bmtinfonet.org\/transplant-article\/what-car-t-cell-therapy"},{"key":"2026092107100876000_14.9.e015963.280","unstructured":"Guidelines for patients: NCCN. n.d. Available: https:\/\/www.nccn.org\/patientresources\/patient-resources\/guidelines-for-patients"},{"key":"2026092107100876000_14.9.e015963.281","article-title":"Benefits and challenges of cancer peer support groups: A systematic review of qualitative studies","volume":"31","author":"Jablotschkin","year":"2022","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2026092107100876000_14.9.e015963.282","unstructured":"Therapeutic resources: National cancer insititute, center for cancer research. n.d. Available: https:\/\/ccr.cancer.gov\/pediatric-psycho-oncology\/ppop-therapeutic-resources"},{"key":"2026092107100876000_14.9.e015963.283","unstructured":"Children\u2019s Oncology Group COG patient and family education resources. n.d. Available: https:\/\/www.childrensoncologygroup.org\/cog-family-handbook"},{"key":"2026092107100876000_14.9.e015963.284","unstructured":"Voicing my choices: National institute of health. n.d. Available: https:\/\/ccr.cancer.gov\/sites\/default\/files\/2025-04\/Voicing%20My%20Choices_%20Aug%202,%202024.pdf%20v2.pdf"},{"key":"2026092107100876000_14.9.e015963.285","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.blre.2016.04.001","article-title":"Extramedullary acute myelogenous leukemia","volume":"30","author":"Solh","year":"2016","journal-title":"Blood Rev"},{"key":"2026092107100876000_14.9.e015963.286","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026092107100876000_14.9.e015963.287","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.01.576","article-title":"A Retrospective Analysis of Advanced Directive Completion and End-of-Life Location in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"31","author":"Shea","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"key":"2026092107100876000_14.9.e015963.288","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/jpm.2015.0327","article-title":"The Impact of Advance Directives on End-of-Life Care for Adolescents and Young Adults Undergoing Hematopoietic Stem Cell Transplant","volume":"19","author":"Needle","year":"2016","journal-title":"J Palliat Med"},{"key":"2026092107100876000_14.9.e015963.289","first-page":"605","article-title":"Fertility and CAR T-cells: Current practice and future directions","volume":"28","author":"Ligon","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026092107100876000_14.9.e015963.290","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/humrep\/deac249","article-title":"Live birth rate after female fertility preservation for cancer or haematopoietic stem cell transplantation: a systematic review and meta-analysis of the three main techniques; embryo, oocyte and ovarian tissue cryopreservation","volume":"38","author":"Fraison","year":"2023","journal-title":"Hum Reprod"},{"key":"2026092107100876000_14.9.e015963.291","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1188\/15.ONF.E91-E101","article-title":"Patient-Reported Symptoms and Quality of Life in Adults With Acute Leukemia: A Systematic Review","volume":"42","author":"Leak Bryant","year":"2015","journal-title":"ONF"},{"key":"2026092107100876000_14.9.e015963.292","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/pbc.25468","article-title":"Quality of life among pediatric patients with cancer: Contributions of time since diagnosis and parental chronic stress","volume":"62","author":"Hamner","year":"2015","journal-title":"Pediatric Blood & Cancer"},{"key":"2026092107100876000_14.9.e015963.293","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/NCC.0000000000000433","article-title":"Quality of Life and Its Predictors Among Children and Adolescents With Cancer","volume":"40","author":"Pan","year":"2017","journal-title":"Cancer Nurs"},{"key":"2026092107100876000_14.9.e015963.294","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912366","article-title":"Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2026092107100876000_14.9.e015963.295","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/hematology.2023000518","article-title":"Barriers to accessing cellular therapy for patients receiving care in community practices","volume":"2023","author":"Nze","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026092107100876000_14.9.e015963.296","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7305"},{"key":"2026092107100876000_14.9.e015963.297","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804658"},{"key":"2026092107100876000_14.9.e015963.298","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"2026092107100876000_14.9.e015963.299","unstructured":"Surveillance E, End Results Program (SEER) . Cancer stat facts: leukemia-acute lymphocytic leukemia (ALL). Bethesda, MD National Cancer Institute."},{"key":"2026092107100876000_14.9.e015963.300","unstructured":"Surveillance E, End Results Program (SEER) . Cancer stat facts: leukemia-acute myeloid leukemia (AML). Bethesda, MD National Cancer Institute."},{"key":"2026092107100876000_14.9.e015963.301","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026092107100876000_14.9.e015963.302","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3032"},{"key":"2026092107100876000_14.9.e015963.303","doi-asserted-by":"crossref","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"2026092107100876000_14.9.e015963.304","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"2026092107100876000_14.9.e015963.305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1200\/OP.22.00713","article-title":"Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy","volume":"19","author":"Marar","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026092107100876000_14.9.e015963.306","unstructured":"FDA approves labeling changes that include a boxed warning for immune effector cell-associated enterocolitis following treatment with ciltacabtagene autoleucel (carvykti, janssen biotech, inc.). FDA; 2025. Available: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fda-approves-labeling-changes-include-boxed-warning-immune-effector-cell-associated-enterocolitis"},{"key":"2026092107100876000_14.9.e015963.307","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02276-w"},{"key":"2026092107100876000_14.9.e015963.308","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.2025028964","article-title":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy","volume":"146","author":"Kaulen","year":"2025","journal-title":"Blood"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:12:12Z","timestamp":1789999932000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":308,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015963"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015963","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}